15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Aurinia Pharmaceuticals Inc, 2 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $15.00 to $21.00, a moderate spread. The average target of $17.25 sits 15% above the current $14.95. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees revenue growth near 15% this year and 18% next, consensus EPS building from about $0.24 next quarter toward $1.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy250%
Hold250%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Aurinia Pharmaceuticals Inc.
As of Jul, 1 of 3 firms rate AUPH a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AUPH EPS & revenue forecast
EPS · NEXT QUARTER
$0.24
Range $0.20 – $0.28 · 5 analysts · +3% YoY
Next period, 5 analysts expect Aurinia Pharmaceuticals Inc to earn $0.24 a share (range $0.20 – $0.28), versus $0.23 a year earlier. Full-year consensus is $0.95, growing to $1.11 the year after.
REVENUE · NEXT QUARTER
$82.5M
Range $80.4M – $89.3M · 5 analysts · +12% YoY
Revenue is expected to reach $82.5M (range $80.4M – $89.3M), +12.0% year-over-year. Full-year consensus is $325.8M, rising to $383.8M next year.
Top analysts covering Aurinia Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AUPH.
#1
Ed Arce
HC Wainwright & Co. · Rank #107
Buy
$13.00-13.0% to target
Overall win rate
44%
+ Follow
#2
Arthur He
HC Wainwright & Co. · Rank #150
Buy
$17.00+13.8% to target
Overall win rate
48%
+ Follow
#3
Joseph Schwartz
Leerink Partners
Hold
$16.00+7.1% to target
Coverage
—
+ Follow
#4
MR
Maury Raycroft
Jefferies
Buy
$21.00+40.5% to target
Coverage
—
+ Follow
#5
DM
Douglas Miehm
RBC Capital
Hold
$15.00+0.4% to target
Coverage
—
+ Follow
AUPH stock forecast FAQ
What is AUPH's average 12-month price target?+
The 4 analysts with a live target average $17.25 for Aurinia Pharmaceuticals Inc over the next 12 months, ranging from a $21.00 high to a $15.00 low.
Is AUPH stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 2 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AUPH?+
The Street-high target is $21.00 (Jefferies), and the Street-low is $15.00 (RBC Capital). The average of all 4 active targets is $17.25.
How many Wall Street analysts cover AUPH?+
4 analysts have an active rating on Aurinia Pharmaceuticals Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering AUPH?+
Among analysts who currently cover AUPH, Ed Arce of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #107). Their current call is Buy with a $13.00 target.
What is Aurinia Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.24 per share (range $0.20 – $0.28) across 5 analysts. Full-year EPS is projected at $0.95, rising to $1.11 the following year.
How much revenue is Aurinia Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $82.5M (range $80.4M – $89.3M). Full-year revenue is projected at $325.8M, growing to $383.8M next year.
Have analysts been upgrading or downgrading AUPH lately?+
As of Jul, 1 of 3 firms rate AUPH a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AUPH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
